Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -714.55 Million SEK | -42.03% |
| 2022 | -554.25 Million SEK | -2.04% |
| 2021 | -538.83 Million SEK | -29.79% |
| 2020 | -413.08 Million SEK | -17.79% |
| 2019 | -352.21 Million SEK | -43.94% |
| 2018 | -245.47 Million SEK | -42.01% |
| 2017 | -172.3 Million SEK | -60.0% |
| 2016 | -107.6 Million SEK | -65.09% |
| 2015 | -65.21 Million SEK | -179.66% |
| 2014 | -28.12 Million SEK | -33.63% |
| 2013 | -17.44 Million SEK | -6.83% |
| 2012 | -16.33 Million SEK | 41.44% |
| 2011 | -24.28 Million SEK | -39.52% |
| 2010 | -19.99 Million SEK | -30.17% |
| 2009 | -15.35 Million SEK | 0.75% |
| 2008 | -15.47 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -181.41 Million SEK | -17.68% |
| 2024 Q3 | -116.92 Million SEK | 35.55% |
| 2024 Q1 | -154.15 Million SEK | -24.07% |
| 2023 Q1 | -182.34 Million SEK | -47.09% |
| 2023 Q3 | -202.15 Million SEK | 11.51% |
| 2023 FY | - SEK | -42.03% |
| 2023 Q4 | -112.33 Million SEK | 44.43% |
| 2023 Q2 | -228.45 Million SEK | -25.28% |
| 2022 Q2 | -167.83 Million SEK | -24.3% |
| 2022 Q1 | -135.02 Million SEK | 17.27% |
| 2022 FY | - SEK | -2.04% |
| 2022 Q4 | -123.96 Million SEK | 11.13% |
| 2022 Q3 | -139.49 Million SEK | 16.89% |
| 2021 Q2 | -132.35 Million SEK | -27.65% |
| 2021 Q1 | -103.68 Million SEK | 0.32% |
| 2021 FY | - SEK | -29.79% |
| 2021 Q3 | -148.17 Million SEK | -11.95% |
| 2021 Q4 | -163.21 Million SEK | -10.15% |
| 2020 FY | - SEK | -17.79% |
| 2020 Q1 | -91.35 Million SEK | 16.63% |
| 2020 Q2 | -101.82 Million SEK | -11.47% |
| 2020 Q3 | -123.44 Million SEK | -21.23% |
| 2020 Q4 | -104.01 Million SEK | 15.74% |
| 2019 Q4 | -109.57 Million SEK | -17.57% |
| 2019 Q3 | -93.19 Million SEK | -11.36% |
| 2019 Q2 | -83.68 Million SEK | -15.14% |
| 2019 Q1 | -72.68 Million SEK | 10.73% |
| 2019 FY | - SEK | -43.94% |
| 2018 FY | - SEK | -42.01% |
| 2018 Q1 | -46.62 Million SEK | 4.55% |
| 2018 Q4 | -81.41 Million SEK | -34.56% |
| 2018 Q3 | -60.5 Million SEK | -2.95% |
| 2018 Q2 | -58.76 Million SEK | -26.05% |
| 2017 Q3 | -37.43 Million SEK | 16.63% |
| 2017 Q4 | -48.84 Million SEK | -30.47% |
| 2017 FY | - SEK | -60.0% |
| 2017 Q1 | -44.82 Million SEK | -33.91% |
| 2017 Q2 | -44.9 Million SEK | -0.17% |
| 2016 Q1 | -19.94 Million SEK | -4.49% |
| 2016 FY | - SEK | -65.09% |
| 2016 Q3 | -26.95 Million SEK | 12.13% |
| 2016 Q4 | -33.47 Million SEK | -24.2% |
| 2016 Q2 | -30.67 Million SEK | -53.79% |
| 2015 FY | - SEK | -179.66% |
| 2015 Q1 | -10.46 Million SEK | 18.08% |
| 2015 Q3 | -13.92 Million SEK | 38.09% |
| 2015 Q2 | -22.49 Million SEK | -115.07% |
| 2015 Q4 | -19.08 Million SEK | -37.06% |
| 2014 Q3 | -5.42 Million SEK | -12.14% |
| 2014 Q4 | -12.76 Million SEK | -135.53% |
| 2014 Q1 | -5.85 Million SEK | -31.8% |
| 2014 Q2 | -4.83 Million SEK | 17.47% |
| 2014 FY | - SEK | -33.63% |
| 2013 Q3 | -4.44 Million SEK | -3.47% |
| 2013 Q2 | -4.29 Million SEK | 0.0% |
| 2013 Q4 | -4.44 Million SEK | 0.0% |
| 2013 Q1 | -4.29 Million SEK | -24.89% |
| 2013 FY | - SEK | -6.83% |
| 2012 Q4 | -3.43 Million SEK | 0.0% |
| 2012 FY | - SEK | 41.44% |
| 2011 FY | - SEK | -39.52% |
| 2010 FY | - SEK | -30.17% |
| 2009 FY | - SEK | 0.75% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -237.61 Million SEK | -200.72% |
| Ziccum AB (publ) | -20.34 Million SEK | -3412.703% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 35727800.0% |
| BioArctic AB (publ) | 275.38 Million SEK | 359.473% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -34253.558% |
| Mendus AB (publ) | -97.84 Million SEK | -630.284% |
| Genovis AB (publ.) | 64.57 Million SEK | 1206.6% |
| Intervacc AB (publ) | -68.98 Million SEK | -935.886% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -5220.185% |
| Active Biotech AB (publ) | -43.88 Million SEK | -1528.168% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 2375.36% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -1203.788% |
| Aptahem AB (publ) | -10 Million SEK | -7038.953% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | -125.08% |
| Kancera AB (publ) | -61.88 Million SEK | -1054.574% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 6287.15% |
| Fluicell AB (publ) | -25.91 Million SEK | -2657.405% |
| Saniona AB (publ) | -69.69 Million SEK | -925.259% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -5803.453% |
| Biovica International AB (publ) | -119.5 Million SEK | -497.923% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -1592.293% |
| AcouSort AB (publ) | -16.7 Million SEK | -4177.998% |
| Xintela AB (publ) | -53.47 Million SEK | -1236.339% |
| Abliva AB (publ) | -93.6 Million SEK | -663.347% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | -123.928% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -2567.939% |
| OncoZenge AB (publ) | 7.26 Million SEK | 9934.214% |
| Amniotics AB (publ) | -27.14 Million SEK | -2532.554% |
| 2cureX AB (publ) | -35.13 Million SEK | -1933.681% |
| CombiGene AB (publ) | -35.33 Million SEK | -1922.167% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -4926.053% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | -94.276% |
| Camurus AB (publ) | 562.54 Million SEK | 227.022% |
| Corline Biomedical AB | -1.69 Million SEK | -42156.298% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -312.265% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -1829.975% |
| I-Tech AB | 30.34 Million SEK | 2454.767% |
| Cyxone AB (publ) | -20.41 Million SEK | -3400.314% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -597.446% |
| Biosergen AB | 228 Thousand SEK | 313500.877% |
| Cantargia AB (publ) | -284.31 Million SEK | -151.325% |
| NextCell Pharma AB | -40.98 Million SEK | -1643.446% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -320.784% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -4082.467% |
| Nanologica AB (publ) | -62.11 Million SEK | -1050.299% |
| SynAct Pharma AB | -222.7 Million SEK | -220.858% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -1529.133% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 231038.584% |
| LIDDS AB (publ) | -39.67 Million SEK | -1701.245% |
| Lipum AB (publ) | -37.11 Million SEK | -1825.036% |
| BioInvent International AB (publ) | -312.7 Million SEK | -128.506% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 1701459.556% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -208.5% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -8008.434% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -521.854% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -3549.594% |
| Simris Alg AB (publ) | -22.36 Million SEK | -3095.251% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -407.312% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | -153.358% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -558.223% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -6130.308% |